Drug Profile
L 696418
Latest Information Update: 09 Mar 1999
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antirheumatics
- Mechanism of Action Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Osteoarthritis
Most Recent Events
- 09 Mar 1999 No-Development-Reported for Osteoarthritis in USA (Unknown route)
- 22 Jan 1996 New profile
- 22 Jan 1996 Preclinical development for Osteoarthritis in USA (Unknown route)